At ASCO 2026, izalontamab brengitecan became the first bispecific antibody-drug conjugate to improve both progression-free and overall survival in triple-negative breast cancer. Inside the EGFRxHER3 mechanism, the Phase 3 trial…
More than thirty targeted protein degraders are now in human trials, with the first Phase 3 readouts arriving in 2026. Inside the vepdegestrant breast cancer data, the BTK degrader race,…
A major study being presented this week at the American Society of Clinical Oncology’s annual meeting found that patients with early-stage cancer who took GLP-1 receptor agonists were 38 to…
AI drug discovery is not one breakthrough. It is a stack of tools for target discovery, molecule design, toxicity prediction, clinical trials, and repurposing — each with a different burden…
The AI drug discovery market is projected to grow from $8.8 billion in 2026 to $114.4 billion by 2033. The bigger story is whether AI can turn better maps of…
As of May 2026, more than 75 AI-discovered drugs are in human trials. Inside the Insilico IPF Phase 2 program, Isomorphic Labs partnerships with Novartis and Lilly, Recursion’s Phase 2…
Lipoprotein(a) is one of the most powerful inherited cardiovascular risk factors ever described, affecting roughly 1.4 billion people globally. After 60 years without a drug, three Phase 3 outcomes trials…
A new KRAS-targeting oral drug called daraxonrasib has nearly doubled survival in metastatic pancreatic cancer, with median overall survival of 13.2 months versus 6.7 months on chemotherapy in the landmark…
A decade of senolytic research is converging into something new. Inside the Mayo Clinic dasatinib quercetin work, the AFFIRM-LITE fisetin trial, Rubedo’s March 2026 Phase 1 readout of RLS-1496, and…
An estimated 1.4 billion people globally carry elevated lipoprotein(a), a genetically inherited cardiovascular risk factor that statins do not lower. Inside the biology of Lp(a), why the science went quiet…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.